查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929555

球蟲疫苗市場按產品類型、動物類型、給藥途徑、銷售形式、最終用戶、分銷管道分類，全球預測（2026-2032年）

Coccidiosis Vaccines Market by Product Type, Animal Type, Administration Route, Sales Mode, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，球蟲疫苗市場規模將達到 5.8084 億美元，到 2026 年將成長至 6.3036 億美元，到 2032 年將達到 9.1537 億美元，複合年成長率為 6.71%。

主要市場統計數據
基準年 2025 5.8084億美元
預計年份：2026年 6.3036億美元
預測年份：2032年 9.1537億美元
複合年成長率 (%) 6.71%

本文簡要概述了目前影響家禽球球蟲疫苗引入決策的科學進展、商業性壓力和營運重點。

全球家禽業持續與球蟲作鬥爭，這種頑固的感染疾病嚴重損害禽群健康、生產力和農場盈利。隨著相關人員探索傳統化療的替代方案，疫苗已成為綜合控制方案的核心，這些方案旨在平衡動物福利、生產效率以及抗菌藥物使用方面的監管壓力。本執行摘要總結了影響疫苗領域的科學、商業性和監管趨勢，揭示了產品創新、給藥方式和分銷動態如何相互作用並影響疫苗的推廣管道。

科學突破、營運需求和監管變化如何共同重塑家禽健康管理中疫苗研發的優先事項和交付管道

球蟲疫苗產業正經歷一場變革，這場變革是由科學、生產系統和監管等多面向因素共同推動的。分子生物學和免疫學的進步加速了重組疫苗和次單位疫苗候選產品的研發，使得篩選能夠拓寬保護譜並降低反應原性的目標抗原成為可能。同時，載體疫苗平台和生產流程的改進降低了企業研發差異化產品的技術門檻，而精準給藥策略則使疫苗更適合大規模商業化生產。

針對影響美國境內或與美國合作的疫苗相關人員所面臨的關稅變化，制定相應的戰略應對措施，以促進供應鏈重組、本地化投資和商業合約的發展。

美國於2025年推出並調整的關稅，為支持疫苗生產和分銷的國際供應鏈帶來了新的成本和戰略複雜性。依賴跨境採購抗原、佐劑和專用反應器的製造商面臨著採購不確定性的增加，這影響了庫存計劃和供應商多元化策略。值得注意的是，關稅帶來的成本壓力往往會加速在地化進程，鼓勵區域製造投資和供應夥伴關係關係，從而降低貿易波動帶來的風險。

一個複雜的細分框架，將產品平台、管理路徑、客戶類型和分銷管道與營運採納和商業性成功聯繫起來。

了解需求促進因素和實施障礙需要明確區分產品類型、動物類型、給藥途徑、最終用戶、分銷管道和銷售形式。以減毒活病毒疫苗、去活化疫苗、重組疫苗、次單位疫苗和載體疫苗類型對產品進行分類，會產生顯著不同的商業性影響。減毒活病毒疫苗平台具有成熟的免疫抗原性特徵和操作熟練度，但其特徵在於存在早期株和野生型變異株，這些減毒活病毒疫苗在減毒程度、排放動力學和生產流程要求方面各不相同。同時，重組疫苗和次單位疫苗候選產品優先考慮安全性和抗原特異性，通常需要先進的生產能力和低溫運輸供應。

區域監管重點、生產規模和分銷能力如何共同決定全球家禽市場的商業性通路和市場接受趨勢？

區域趨勢正在顯著影響美洲、歐洲、中東和非洲以及亞太地區的研發重點、製造地和市場推廣策略。在美洲，監管機構對食品安全、動物福利以及大型加工企業間整合的重視，正在影響對可擴展疫苗解決方案和數據驅動型綜合健康計劃的需求。該地區還擁有強大的契約製造，商業農場與大型供應商合作以獲得全面服務的趨勢，正在加速採用管理效率更高的平台。

競爭定位和合作策略將決定哪些公司能夠在禽類健康領域將科學差異化與持續應用和規模化相結合。

球蟲疫苗領域的競爭反映了擁有成熟平台能力的現有企業與致力於研發新型抗原和遞送技術的新興參與企業之間的博弈。現有企業利用長期累積的田間數據、現有的分銷網路和技術支援團隊，並與大型商業生產商和一體化營業單位保持良好的合作關係。他們通常專注於在菌株選擇、生產效率和劑量相容性方面進行漸進式改進，以維護現有基本客群並確保供應的連續性。

企業應優先採取切實有效、影響深遠的策略措施，以加速技術採納、減少商業性摩擦並建立具有韌性的供應鏈和分銷模式。

為了在不斷變化的環境中實現永續價值，產業領導者必須務實地結合產品創新、協作和商業性靈活性。投資於能夠降低反應原性並維持廣譜保護的平台技術，將有助於製造商同時滿足動物福利期望和生產需求。同時，優先考慮能夠融入孵化場和養殖場工作流程的給藥途徑（例如卵內、水源性等），將減少營運摩擦，而這些摩擦往往會阻礙大規模應用。

我們採用透明、依證的研究途徑，結合關鍵相關人員的意見、技術檢驗和供應鏈分析，從而產生可執行的商業性洞察。

本分析採用透明、可重複的調查方法，結合一手與二手研究，兼顧技術嚴謹性和實際應用價值。一級資訊來源包括對商業領袖、獸醫和生產經理的結構化訪談，以及與免疫學家和生產專家的技術諮詢，以檢驗菌株特徵、給藥可行性和操作限制。二級資訊來源包括同儕審查文獻、監管指導文件和公開文件，以支援該平台的功能、安全性和核准流程。

一項綜合分析重點闡述如何整合策略，將技術進步轉化為永續的疾病控制和商業性價值。

分析結果展現了一幅務實創新的整體情況。科學進步正在拓展球蟲防治手段，但商業性成功取決於能否將這些進步與現代家禽生產的實際情況以及不斷發展的貿易和法律規範相契合。將生物分化技術與可控的交付模式和完善的售後支援相結合的研發者最有可能實現持續推廣。同時，關稅波動和區域監管差異也提升了供應鏈韌性和社區夥伴關係的策略價值。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章球蟲疫苗市場（依產品類型分類）

  • 減毒活病毒疫苗
    • 早熟型
    • 野生型
  • 去活化疫苗
  • 重組疫苗
  • 次單位疫苗
  • 載體疫苗

第9章 依動物類型球蟲疫苗市場

  • 肉雞
  • 產蛋雞
  • 火雞

第10章球蟲疫苗市場依給藥途徑分類

  • 注射
  • 口服
    • 飼料添加劑型
    • 卵內給藥
    • 飲用水管理

第11章 依銷售類型球蟲疫苗市場

  • 非處方藥
  • 處方藥

第12章球蟲疫苗市場（依最終用戶分類）

  • 商業家禽養殖場
  • 綜合家禽生產商
  • 研究所

第13章球蟲疫苗市場（依通路分類）

  • 直銷
  • 經銷商
  • 線上管道

第14章球蟲疫苗市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章球蟲疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國球球蟲疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國球蟲疫苗市場

17. 中國球蟲疫苗市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Animalcare Group plc
  • APHA
  • BIMeda, Inc.
  • Bioproperties（Hubei）BIoTechnology Co., Ltd.
  • Ceva Sante Animale SA
  • CEVAC
  • Elanco Animal Health Incorporated
  • Elanco Operations LLC
  • Hester Biosciences Limited
  • Huvepharma AD
  • IDT Biologika GmbH
  • ImmuCell Corporation
  • Indian Immunologicals Limited
  • Intervet International BV
  • Laboratorios Hipra, SA
  • Lohmann Animal Health International GmbH
  • Merck Sharp & Dohme Corp.
  • MSD Animal Health UK Limited
  • Pharmaq AS
  • Phibro Animal Health Corporation
  • The Chemo-Sero-Therapeutic Research Institute（Kaketsuken）
  • Vaxxinova International BV
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-0A3806951816

The Coccidiosis Vaccines Market was valued at USD 580.84 million in 2025 and is projected to grow to USD 630.36 million in 2026, with a CAGR of 6.71%, reaching USD 915.37 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 580.84 million
Estimated Year [2026] USD 630.36 million
Forecast Year [2032] USD 915.37 million
CAGR (%) 6.71%

A concise orienting overview that frames current scientific advances, commercial pressures, and operational priorities shaping coccidiosis vaccine decision-making in poultry

The global poultry sector continues to contend with coccidiosis as one of the most persistent infectious diseases undermining flock health, productivity, and farm-level profitability. As stakeholders pursue alternatives to traditional chemotherapeutics, vaccines have become central to integrated control programs that balance animal welfare, production efficiency, and regulatory pressures around antimicrobial use. This executive summary synthesizes scientific, commercial, and regulatory developments shaping the vaccine landscape, highlighting how product innovation, administration practices, and distribution dynamics intersect to influence adoption pathways.

This report places particular emphasis on product differentiation across attenuated live and next-generation platforms, shifts in administration practices such as in-ovo and in-water delivery, and the evolving roles of commercial poultry producers and integrated enterprises in procurement and deployment. It integrates cross-cutting themes including biosecurity, supply chain resilience, and the influence of trade policy on manufacturing and sourcing decisions. Ultimately, the introduction frames the critical choices facing research and commercial leaders seeking to translate efficacy data into scalable, cost-effective interventions that reduce disease burden while meeting consumer and regulatory expectations.

How scientific breakthroughs, operational demands, and regulatory shifts are jointly redefining vaccine development priorities and adoption pathways in poultry health

The coccidiosis vaccine landscape is in the midst of transformative shifts driven by converging forces in science, production systems, and regulation. Advances in molecular biology and immunology have accelerated the development of recombinant and subunit vaccine candidates, enabling targeted antigen selection that can reduce reactogenicity while broadening protective profiles. Concurrently, improvements in vector vaccine platforms and manufacturing processes have lowered technical barriers for companies seeking differentiated offerings, and precision delivery approaches are making vaccines more compatible with large-scale commercial operations.

At the production level, integrated poultry producers and large commercial farms are exerting greater influence over procurement decisions, favoring products that demonstrate operational compatibility with mass administration methods and that align with welfare and sustainability commitments. Administration routes such as in-ovo and in-water delivery are gaining traction because they reduce handling time and labor intensity while supporting more uniform immunization across cohorts. Regulatory landscapes have also tightened around antimicrobial stewardship, indirectly amplifying the commercial imperative to adopt effective vaccination regimens. Taken together, these shifts are raising the bar for product developers to demonstrate not only biological efficacy but also delivery practicality, manufacturability, and traceable safety profiles that meet buyers' operational realities.

Strategic responses to tariff changes that are reshaping supply chains, localization investments, and commercial agreements for vaccine stakeholders operating in and with the United States

The introduction and adjustment of U.S. tariffs in 2025 have introduced new layers of cost and strategic complexity for international supply chains that underpin vaccine production and distribution. Manufacturers that rely on cross-border inputs for antigen production, adjuvants, or specialized bioreactors face increased procurement uncertainty, which, in turn, influences inventory planning and supplier diversification strategies. Importantly, tariff-induced cost pressure tends to accelerate localization efforts by incentivizing regional manufacturing investments and supply partnerships that reduce exposure to trade volatility.

For exporters and multinational firms serving the U.S. market, tariff changes have encouraged re-evaluation of pricing strategies, contractual terms with distributors, and the structure of commercial agreements to absorb or pass through increased landed costs. Meanwhile, distributors and direct sales channels are adapting by seeking value-added services-such as bundled logistics or inventory financing-to mitigate margin compression. On the policy side, heightened tariff environments have amplified the importance of demonstrating domestic value creation through local production, joint ventures, and technology transfer initiatives. Consequently, strategic responses to tariff shifts are not limited to short-term cost management but extend to long-term portfolio localization, route-to-market redesign, and strengthened ties with domestic stakeholders to preserve market access and competitiveness.

A nuanced segmentation framework linking product platforms, administration pathways, customer types, and sales channels to operational adoption and commercial success

Understanding demand drivers and adoption barriers requires clear segmentation across product type, animal type, administration route, end user, distribution channel, and sales mode. When products are categorized by type-Attenuated Live Vaccine, Inactivated Vaccine, Recombinant Vaccine, Subunit Vaccine, and Vector Vaccine-the commercial implications vary markedly: attenuated live platforms bring established immunogenicity profiles and operational familiarity, with attenuated live options further characterized by Precocious strains and Wild Type variants that differ in attenuation, shedding dynamics, and production handling requirements. In contrast, recombinant and subunit candidates prioritize safety and antigen specificity, often demanding advanced manufacturing capabilities and cold chain assurances.

Animal-type segmentation-broiler chickens, layer chickens, and turkeys-drives distinct dosing strategies, timing considerations, and economic thresholds for vaccine interventions because production cycles and value-per-bird differ across these groups. Administration-route segmentation offers operational trade-offs: injection-based approaches deliver precise dosing but increase labor and stress on birds, while oral delivery methods such as in-feed, in-ovo, and in-water administration facilitate mass immunization and align with automated production workflows, although they require formulation stability and robust delivery protocols. End-user distinctions among commercial poultry farms, integrated poultry producers, and research institutes influence procurement sophistication and adoption timelines; large integrated producers often demand scalable administration solutions and data integration, whereas research institutes prioritize novel platforms and experimental flexibility. Distribution-channel segmentation across direct sales, distributors, and online channels affects lead times, after-sales support, and cold chain integrity, with direct sales enabling closer technical collaboration and online channels offering efficiency for standardized products. Finally, sales-mode segmentation into Over-The-Counter and Prescription pathways shapes regulatory compliance, veterinary oversight, and purchaser responsibility for on-farm use. Taken together, these intersecting segmentation lenses create a complex decision matrix for developers and purchasers, requiring tailored value propositions that match product attributes to operational realities and regulatory obligations.

How regional regulatory priorities, production scales, and distribution capabilities converge to determine commercial pathways and adoption dynamics across global poultry markets

Regional dynamics materially shape research priorities, manufacturing footprints, and route-to-market strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, regulatory emphasis on food safety, animal welfare, and consolidation among large processors influences demand for scalable vaccine solutions and integrated data-driven health programs. This region also exhibits robust contract manufacturing capacity and a propensity for commercial farms to partner with large suppliers for bundled services, which accelerates diffusion of administratively efficient platforms.

In Europe, Middle East & Africa, regulatory stringency and consumer expectations around antibiotic stewardship create a favorable environment for vaccines that demonstrate clear welfare and residue advantages, while diverse farming systems in the EMEA region necessitate flexible delivery options that can be adapted to smallholder as well as commercial contexts. The Asia-Pacific region remains a focal point for both production volume and innovation, driven by large poultry populations, variable regulatory regimes, and growing investment in regional manufacturing. In this region, in-ovo and in-water administration solutions are particularly attractive because they scale with high-throughput hatchery and grow-out operations. Across these geographies, manufacturers must tailor registration approaches, distribution models, and technical support to local regulatory frameworks and producer practices, recognizing that success hinges on combining scientific differentiation with logistical suitability and culturally informed commercial engagement.

Competitive positioning and collaboration strategies that determine which companies translate scientific differentiation into sustained adoption and operational scale in poultry health

Competitive dynamics in the coccidiosis vaccine space reflect an interplay between legacy players with established platform capabilities and newer entrants pursuing novel antigen and delivery technologies. Established manufacturers leverage longitudinal field data, existing distribution networks, and technical support teams to maintain trust among large commercial producers and integrated operations. They often focus on incremental improvements in strain selection, manufacturing efficiency, and administration compatibility to protect installed bases and demonstrate continuity of supply.

Emerging companies and specialized biotech firms concentrate on recombinant, subunit, and vector-based platforms, emphasizing differentiated safety profiles, targeted immune responses, and potential compatibility with precision delivery methods. These companies frequently form strategic alliances with contract manufacturers, hatcheries, and distributor partners to accelerate field trials and scale-up. Across the competitive landscape, collaboration between vaccine developers, integrators, and feed or hatchery operators is becoming a competitive advantage because it shortens adoption cycles and addresses operational barriers to implementation. Intellectual property around antigen constructs and delivery technologies, combined with proven field performance and robust post-market surveillance, will determine which firms secure long-term commercial traction in diverse production environments.

Practical, high-impact strategic moves that companies should prioritize to accelerate adoption, reduce commercial friction, and build resilient supply and distribution models

Industry leaders must adopt a pragmatic mix of product innovation, operational alignment, and commercial agility to capture sustainable value in this evolving environment. Investment in platform technologies that reduce reactogenicity while maintaining broad protective coverage will help manufacturers meet both welfare expectations and production imperatives. Concurrently, prioritizing administration routes that integrate with hatchery and farm workflows-such as in-ovo and in-water options-will lower the operational friction that often impedes adoption at scale.

Strategically, firms should pursue supply-base diversification and regional manufacturing collaborations to mitigate trade-related cost volatility and to meet local regulatory requirements more efficiently. Commercial teams need to design value propositions that extend beyond product performance to include training, cold chain assurance, and post-deployment surveillance services that reduce perceived buyer risk. Finally, forging partnerships with integrators, feed companies, and hatcheries can create bundled solutions that shorten the sales cycle and embed vaccines into standard operating procedures, thereby converting clinical benefits into measurable operational outcomes. Executing on these priorities requires cross-functional alignment between R&D, regulatory, manufacturing, and commercial teams, supported by targeted investments in field validation and customer education.

A transparent, evidence-based research approach blending primary stakeholder input, technical validation, and supply chain mapping to generate actionable commercial intelligence

This analysis synthesizes primary and secondary research under a transparent, reproducible methodology that balances technical rigor with practical relevance. Primary inputs included structured interviews with commercial leaders, veterinarians, and production managers, complemented by technical consultations with immunologists and manufacturing specialists to verify strain characteristics, delivery feasibility, and operational constraints. Secondary inputs encompassed peer-reviewed literature, regulatory guidance documents, and public filings that were used to corroborate platform capabilities, safety profiles, and approval pathways.

Qualitative synthesis emphasized triangulation across sources to identify consistent themes and potential inflection points, while methodological safeguards included cross-validation of interview findings against published evidence and regulatory frameworks. The research team also evaluated route-to-market considerations through supply chain mapping and stakeholder role analysis to ensure recommendations align with real-world procurement and distribution practices. Limitations of the methodology are acknowledged where direct head-to-head field data were not available, and in such instances the analysis highlights evidence gaps and proposes targeted study designs for future validation. The overall approach prioritizes actionable insight generation while maintaining methodological transparency and traceability of analytic judgments.

A synthesis highlighting how integrated scientific, operational, and policy strategies convert technological advances into sustained disease control and commercial value

The cumulative picture emerging from this analysis is one of pragmatic innovation: scientific advances are expanding the toolbox for coccidiosis control, but commercial success depends on aligning those advances with the operational realities of modern poultry production and the shifting contours of trade and regulation. Developers that couple biological differentiation with administratively efficient delivery formats and robust post-market support are most likely to achieve durable adoption. At the same time, tariff dynamics and regional regulatory variability increase the strategic premium on supply chain resilience and localized partnerships.

For decision-makers, the path forward involves prioritizing investments that reduce adoption friction-whether through formulation stability for oral delivery, service models that simplify on-farm implementation, or localized manufacturing that mitigates trade exposure. By integrating scientific rigor with commercial pragmatism and proactive stakeholder engagement, companies can convert technical promise into field impact while supporting broader industry goals around animal health, welfare, and responsible antibiotic use. The conclusion emphasizes that durable progress will arise from coordinated action across R&D, manufacturing, policy engagement, and frontline commercial support.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coccidiosis Vaccines Market, by Product Type

  • 8.1. Attenuated Live Vaccine
    • 8.1.1. Precocious
    • 8.1.2. Wild Type
  • 8.2. Inactivated Vaccine
  • 8.3. Recombinant Vaccine
  • 8.4. Subunit Vaccine
  • 8.5. Vector Vaccine

9. Coccidiosis Vaccines Market, by Animal Type

  • 9.1. Broiler Chickens
  • 9.2. Layer Chickens
  • 9.3. Turkeys

10. Coccidiosis Vaccines Market, by Administration Route

  • 10.1. Injection
  • 10.2. Oral
    • 10.2.1. In-Feed
    • 10.2.2. In-Ovo
    • 10.2.3. In-Water

11. Coccidiosis Vaccines Market, by Sales Mode

  • 11.1. Over-The-Counter
  • 11.2. Prescription

12. Coccidiosis Vaccines Market, by End User

  • 12.1. Commercial Poultry Farms
  • 12.2. Integrated Poultry Producers
  • 12.3. Research Institutes

13. Coccidiosis Vaccines Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Distributors
  • 13.3. Online Channels

14. Coccidiosis Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Coccidiosis Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Coccidiosis Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Coccidiosis Vaccines Market

18. China Coccidiosis Vaccines Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Animalcare Group plc
  • 19.6. APHA
  • 19.7. BIMeda, Inc.
  • 19.8. Bioproperties (Hubei) Biotechnology Co., Ltd.
  • 19.9. Ceva Sante Animale S.A.
  • 19.10. CEVAC
  • 19.11. Elanco Animal Health Incorporated
  • 19.12. Elanco Operations LLC
  • 19.13. Hester Biosciences Limited
  • 19.14. Huvepharma AD
  • 19.15. IDT Biologika GmbH
  • 19.16. ImmuCell Corporation
  • 19.17. Indian Immunologicals Limited
  • 19.18. Intervet International B.V.
  • 19.19. Laboratorios Hipra, S.A.
  • 19.20. Lohmann Animal Health International GmbH
  • 19.21. Merck Sharp & Dohme Corp.
  • 19.22. MSD Animal Health UK Limited
  • 19.23. Pharmaq AS
  • 19.24. Phibro Animal Health Corporation
  • 19.25. The Chemo-Sero-Therapeutic Research Institute (Kaketsuken)
  • 19.26. Vaxxinova International BV
  • 19.27. Vetoquinol S.A.
  • 19.28. Virbac S.A.
  • 19.29. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COCCIDIOSIS VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COCCIDIOSIS VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA COCCIDIOSIS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRECOCIOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRECOCIOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRECOCIOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY WILD TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY WILD TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY WILD TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY VECTOR VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY VECTOR VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY VECTOR VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY BROILER CHICKENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY BROILER CHICKENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY BROILER CHICKENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY LAYER CHICKENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY LAYER CHICKENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY LAYER CHICKENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY TURKEYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY TURKEYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY TURKEYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-OVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-OVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-OVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-WATER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-WATER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY IN-WATER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY OVER-THE-COUNTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY OVER-THE-COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY COMMERCIAL POULTRY FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY COMMERCIAL POULTRY FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY COMMERCIAL POULTRY FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INTEGRATED POULTRY PRODUCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INTEGRATED POULTRY PRODUCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY INTEGRATED POULTRY PRODUCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 168. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 169. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. GCC COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 192. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 195. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. G7 COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 204. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. NATO COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL COCCIDIOSIS VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA COCCIDIOSIS VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY ATTENUATED LIVE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY SALES MODE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA COCCIDIOSIS VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)